Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIIB 100

Next Previous
Drug Profile

BIIB 100

Alternative Names: BIIB-100; KPT 350

Latest Information Update: 20 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Karyopharm Therapeutics
  • Class Anti-inflammatories; Antiepileptic drugs; Antirheumatics; Fluorinated hydrocarbons; Hydrazines; Neuroprotectants; Small molecules; Triazoles
  • Mechanism of Action Exportin 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Amyotrophic lateral sclerosis

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis
  • Preclinical Unspecified
  • Discontinued Brain injuries; Duchenne muscular dystrophy; Epilepsy; Multiple sclerosis; Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 31 Dec 2024 Preclinical trials in Unspecified in USA (PO)
  • 29 Feb 2024 KPT 350 is still in phase I trials for Amyotrophic lateral sclerosis in USA (KARYOPHARM THERAPEUTICS SEC filing, Form 10-K, March 2024)
  • 29 Feb 2024 BIIB 100 is available for licensing as of 22 Mar 2024. https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/1503802/000095017024022650/kpti-20231231.htm

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top